Bio-Rad markets the hexapeptide technology in the form of its ProteoMiner enrichment kits. Since this technology does not rely on antibodies, it can theoretically be applied to multiple sample types.
The Bio-Rad research described in the poster was designed to examine the applicability of ProteoMiner protein enrichment kits for the reduction of high-abundance proteins and enrichment of medium- and low-abundant proteins from heart muscle, HeLa cells, and E. coli protein samples. The scientists discussed the conditions for protein extraction, treatment with ProteoMiner beads, and analysis with 2-D gel electrophoresis.
The group concluded that the technology, first developed for the reduction of high-abundance proteins in serum and plasma, does work with tissues, cell lines, bacterial, and plant samples. They said they found a significant reduction of the top high-abundance proteins in each sample set, as confirmed by mass spectroscopy identification.
In addition, “heart and HeLa cell proteins that have been extracted under denaturing conditions can be used successfully with ProteoMiner protein enrichment kits,” they wrote, adding that “ProteoMiner bead treatment enriches a unique population of proteins not apparent in the untreated samples.”
Because of the removal of greater than 95% of sample protein mass, protein spot numbers for heart, HeLa cells, and E. coli increased 14%–28% following ProteoMiner bead treatment, the team reported.